About EDGAR Online | Login
 
Enter your Email for a Free Trial:
The following is an excerpt from a 8-K SEC Filing, filed by ENDO PHARMACEUTICALS HOLDINGS INC on 1/9/2008.
Previous Section Previous Section
ENDO PHARMACEUTICALS HOLDINGS INC - 8-K - 20080109 - EXHIBIT_99
ENDO PHARMACEUTICALS
JP Morgan Healthcare Conference
January 9, 2008
Exhibit 99.1

2
Accelerating
Our
Growth
©
2008 Endo Pharmaceuticals
Forward-Looking Statements
Except
for
the
historical
information
contained
herein,
this
presentation
contains
“forward-looking
statements”
within
the
meaning
of
the
Private
Securities
Litigation
Reform
Act
of
1995.
Because
these
statements
involve
a
number
of
risks
and
uncertainties,
actual
future
results
may
differ
materially
from
those
expressed
or
implied
by
such
forward-looking
statements.
Factors
that
could
cause
or
contribute
to
such
differences
include,
but
are
not
limited
to,
the
difficulty
of
predicting
FDA
approvals,
results
of
clinical
trials
on
new
products,
acceptance
and
demand
for
new
pharmaceutical
products,
challenges
relating
to
intellectual
property
protection,
the
impact
of
competitive
products
and
pricing,
the
timely
development
and
launch
of
new
products,
a
determination
that
we
are
engaging
in
inappropriate
sales
or
marketing
activities,
including
promoting
the
"off-label"
use
of
our
products,
and
the
risk
factors
listed
from
time
to
time
in
the
Company’s
SEC
reports,
including
the
Company’s
Annual
Report
on
Form
10-K
for
the
fiscal
year
ended
December
31,
2006.

3
Accelerating Our Growth
©
2008 Endo Pharmaceuticals
Key Events in 2007
On track for record sales and earnings in 2007
Adopted new strategic plan
Strengthened executive management team
Strong commercial capability
•
Specialty and PCP sales forces ~700 Reps
•
Managed Care expansion complete
Completed expansion of Clinical Liaison group
Strengthened
IP
estate
for
OPANA
®
with
addition
of
three
patents
to FDA’s Orange Book
Expanded pipeline with innovative pain product AZ-003/EN3294

4
Accelerating Our Growth
©
2008 Endo Pharmaceuticals
2007 Guidance
$1.79–$1.84
Adjusted Diluted EPS
$90–$110M
OPANA
®
ER / OPANA
®
Net Sales
$685–$710M
LIDODERM
®
Net Sales
$1.050–$1.075B
Net Sales

5
Accelerating Our Growth
©
2008 Endo Pharmaceuticals
2008 Guidance
$2.10 -
$2.15
Adjusted Diluted EPS
$1.215 –
$1.240B
Net Sales

6
Accelerating Our Growth
©
2008 Endo Pharmaceuticals
2008 -
Implementing Our Growth Strategy
Deepen and broaden penetration into 
pain market
•
Clinically innovative and differentiated
products
•
Advance current development pipeline
Continue to pursue selective development
of generic products
Use Balance Sheet to Maximize Shareholder Value
Diversify revenue base
•
Product licensing
•
Acquisitions
Drive top-line growth
•
Maximizing potential of key on-market
products
Longer-Term
Near-Term

7
Accelerating Our Growth
©
2008 Endo Pharmaceuticals
$399.0
$595.6
$615.1
$820.2
$909.7
$1,062.0
$1,227.5
2002
2003
2004
2005
2006
2007**
2008**
Net Sales*
Accelerating Our Growth
* Millions, except per share; ** Represents mid-point of company guidance;
†
Includes $0.62 in one-time, non-cash items
$1.03
†
$1.52
$1.08
$0.53
$0.30
Diluted EPS
’02–’08 CAGR 21%

8
Accelerating Our Growth
©
2008 Endo Pharmaceuticals
’03–’07 CAGR 41%*
$178
$309
$419
$698
$567
$0
$200
$400
$600
$800
2003
2004
2005
2006
2007**
LIDODERM
®
–
A Continuing Success Story
* $ Millions; ** Represents mid-point of company guidance
Net Sales

9
Accelerating Our Growth
©
2008 Endo Pharmaceuticals
LIDODERM –
A Well-Protected Franchise
Lidocaine-
Containing Topical
Product that Does Not
Numb the Skin
Submitted Citizen
Petition Late 2006
and Amendments in
Aug. 2007
Protected by Five
Orange Book-Listed
Patents Until 2015
Method of Use
Patents Expiring 2012

10
Accelerating Our Growth
©
2008 Endo Pharmaceuticals
OPANA
®
ER
Broad indication: For the relief of moderate - to - severe
pain in patients requiring continuous, around-the-
clock opioid treatment for an extended period of time
First time oxymorphone available in oral
ER formulation; twice-daily dosing
Proven efficacy in broad range of appropriate
pain patients
Effective pain control shown at stable dose for three
months in clinical trials underscores durability of
OPANA ER’s analgesic effect
Generally well tolerated when titrated effectively*
* Most common adverse events (> 10%) in trials were nausea, constipation,
dizziness, vomiting, pruritus, somnolence, headache, increased sweating, and
sedation

11
Accelerating Our Growth
©
2008 Endo Pharmaceuticals
OPANA Franchise Gaining Broad Acceptance
Strong Rx growth trends
Net
sales
on
track
to
meet
2007
guidance
Managed-care strategy to attain Tier II and competitive access
Responsible promotional and marketing activities
•
Introduced Instant Savings Card program
•
Completed Specialty Force II expansion
•
Initiated new promotional campaign -
4Q07
•
Conducted Key Opinion Leader speaker programs

12
Accelerating Our Growth
©
2008 Endo Pharmaceuticals
OPANA ER Patent Update
Protected by four Orange Book-listed patents covering the
TimeRx controlled-release formulation
Three years of FDA marketing exclusivity through 6/09
Additional patents on file with U.S. PTO
Filed lawsuit against IMPAX on 11/15/07 in response to
Paragraph IV certification notices
•
Asserts infringement of ‘933 and ‘456 patents
•
Seeks declaratory judgment against certifications, citing FDA’s
rescission of IMPAX’s ANDA
IMPAX filed new PIV certification on 12/14/07 that included two
additional patents listed in the Orange Book

13
Accelerating Our Growth
©
2008 Endo Pharmaceuticals
FROVA
®
on Pace for Record Sales in 2007
Net sales in 2006 $40.6 million;
$38.4 million through 9/30/07
Rx growth tracking at 12% YTD
Triptan indicated for acute
treatment of migraine headaches
in adults
Market differentiation based on
low recurrence rate, long half-life

14
Accelerating Our Growth
©
2008 Endo Pharmaceuticals
Evolving Development Pipeline
Phase I
Phase II
Phase III
Filed
Preclinical
Product
(1)  Licensed marketing rights;  (2) Licensed marketing and development rights
FROVA
®
(1)
(Menstrual Migraine)
EN 3267
-
RAPINYL
TM (2)
(Breakthrough Cancer Pain)
EN 3285 -
NAC Oral Rinse
EN 3294/ AZ-003
(2)  
(Inhaled fentanyl Breakthrough Pain)
EN 3269 -
Ketoprofen
Patch
(2)
(Topical –
Soft Tissue Injuries)
EN 3270 –
Sufentanil
Patch
(2)
(Transdermal –
Chronic Pain)

15
Accelerating Our Growth
©
2008 Endo Pharmaceuticals
RAPINYL
®
-
EN 3267 Clinical Trial Update
Positive interim statistical analysis announced 12/17/07
•
Met primary endpoint –
Sum of Pain Intensity Difference from
baseline to 30 minutes (SPID 0-30)
•
Results highly statistically significant ( p =0.0004)
•
Met all secondary endpoints
Statistically significant separation from placebo on mean pain
intensity difference seen as early as 10 minutes
Need to complete Phase III long-term safety study to file NDA

16
Accelerating Our Growth
©
2008 Endo Pharmaceuticals
Ketoprofen Patch EN 3270 –
Clinical Trial Update
Two Phase III Trials Did Not Meet Primary Endpoint
Ankle sprains and strains
Tendonitis/bursitis of shoulder, elbow or knee
Outcome may have been influenced by several factors, including severity of
pain on entry and use of ibuprofen as rescue medication
•
Additional ongoing Phase III trial amended based on these findings
Efficacy Portion of Long-Term OA Safety Study
Shows Positive Results
Positive outcome achieved in double-blind, placebo-controlled portion of
long-term safety study in osteoarthritis flare of the knee
Primary WOMAC at day 14 versus placebo p =0.014
Met secondary outcomes as well

17
Accelerating Our Growth
©
2008 Endo Pharmaceuticals
EN 3285 –
NAC for Oral Mucositis Prevention
About 400,000 patients per year in U.S. develop OM
•
Only current FDA-approved Rx treatment is IV infusion
Market
First of two Phase III trials now underway; approved under
SPA process
Trials
EN 3285
Patent-protected oral rinse formulated using proprietary
ProGelz
®
delivery platform for prevention of oral mucositis
Active ingredient is N-acetyl cysteine
•
FDA-approved amino acid metabolite (anti oxidant)
Ease of use for patients
No systemic side effects
Anticipated
Benefits

18
Accelerating Our Growth
©
2008 Endo Pharmaceuticals
Transdermal Sufentanil Patch -
EN 3270
Profile
Being studied for treatment of
moderate-to-severe chronic pain
Next-generation extended-release
opioid patch
Anticipated
Benefits
Convenience/compliance of seven-day
dosing vs. three-day dosing
Smaller patch ~ 20% the size of Duragesic
Trials
Phase I product characterization ongoing
Phase II trial underway
•
Designed to evaluate conversion from oral opioids

19
Accelerating Our Growth
©
2008 Endo Pharmaceuticals
Inhaled Fentanyl -
EN 3294
Deepening Our Penetration in Pain
Licensed N. American development and commercialization
rights to Alexza’s
AZ-003 (Staccato
®
fentanyl) on 12/27/07
Hand-held drug delivery system for treatment of breakthrough
pain in cancer and non-cancer patients
Currently in Phase I clinical trial development
Financial terms:
•
Up-front fee of $10 million
•
Up to $40 million in milestone payments
•
Undisclosed royalties on net sales

20
Accelerating Our Growth
©
2008 Endo Pharmaceuticals
Novel Approach to Pain Management
EN 3294/AZ-OO3 Profile:
Uses
proprietary
Staccato
delivery
system
•
“Best in class”
inhalation technology
Potential for rapid onset of action
•
Currently unmet need in breakthrough pain
•
Early PK data suggest comparable to intravenous formulation
Potentially tamper-resistant system
Patent protection until 2022

21
Accelerating Our Growth
©
2008 Endo Pharmaceuticals
Summary
Market leadership in pain management
Well-developed commercial capability
Very broad and deep pipeline
Strong financial condition
Clear strategy for sustainable growth

ENDO PHARMACEUTICALS
NASDAQ: ENDP
© 1995-2010 EDGAR Online, Inc. All rights reserved • NASDAQ: EDGR • Solutions for Corporations • Terms of Use • Privacy Statement